Check-Cap (STU:7CC) ROCE % : -58.49% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Check-Cap ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Check-Cap's annualized ROCE % for the quarter that ended in Dec. 2023 was -58.49%.

Check-Cap ROCE % Historical Data

The historical data trend for Check-Cap's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Check-Cap ROCE % Chart

Check-Cap Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-141.58

-115.71

-51.24

-42.24

-52.44

Check-Cap Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-28.82	-48.36	-70.92	-40.09	-58.49

Check-Cap ROCE % Calculation

Check-Cap's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-16.098	/	( ( (42.896 - 3.217)	+	(22.941 - 1.22) )	/ 2 )
	=	-16.098	/	( (39.679	+	21.721)	/ 2 )
	=	-16.098	/	30.7
	=	-52.44 %

Check-Cap's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-13.86	/	( ( (27.201 - 1.532)	+	(22.941 - 1.22) )	/ 2 )
	=	-13.86	/	( ( 25.669	+	21.721 )	/ 2 )
	=	-13.86	/	23.695
	=	-58.49 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Check-Cap (STU:7CC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Check-Cap ROCE % Related Terms

Thank you for viewing the detailed overview of Check-Cap's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Check-Cap Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Check-Cap Ltd (STU:7CC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CHEK:USA

Address

29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000

Website

https://www.check-cap.com

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Check-Cap Headlines

No Headlines